Biotech Breakthroughs: How Hoth Therapeutics ($HOTH) Is Tackling Cancer, Obesity, and Alzheimer’s

What if a drug could help chemotherapy patients continue treatment without painful side effects? Hoth Therapeutics (NASDAQ: HOTH) is making that possible by developing innovative treatments that address unmet medical needs and help patients maintain their therapy safely.

In this interview, CEO Robb Knie discusses HT-001, the company’s lead drug currently in Phase 2 trials for chemotherapy-induced rash, and HT-KIT, which shows promise in cancer treatment. He also shares how the company is advancing programs for Alzheimer’s and obesity, including an obesity drug licensed from the U.S. Department of Veterans Affairs.

With a diversified pipeline, a patient-focused approach, and strategic use of AI to de-risk and accelerate development, Hoth Therapeutics is positioning itself as a biotech company to watch.

Learn more about Hoth Therapeutics: https://hoththerapeutics.com

00:00 Introduction
01:02 Targeting Unmet Patient Needs: Hoth’s Innovative Pipeline
02:50 HT001 Improving Life During Chemotherapy
04:02 HTKIT: A Breakthrough Preclinical Cancer Treatment
04:55 Diversified Pipeline Strategy & AI-Driven Drug Discovery
06:03 Bringing Life-Changing Drugs to Market
07:44 Why Hoth Therapeutics Stands Out: Innovation, Speed & Multiple Opportunities
09:34 Hoth Therapeutics’ Unique Edge

#BiotechInvesting #MedicalInnovation #PharmaInnovation #Healthcare #AlzheimersResearch #HealthTreatments #Biotech #CancerTreatment #stockstobuy #stockstowatch #stockstotrade

➡ Check out https://StockTA.com for FREE Stock Technical Analysis and Trading Tools to make smarter investment decisions.

FOLLOW STOCKS TO WATCH ON:

Twitter: https://twitter.com/stocks2watch_
TikTok: https://www.tiktok.com/@globalonemedia
Spotify: https://open.spotify.com/show/6VzOJFG6lv85shwRyVEhf7?si=0a3313957c5b455a
________________

DISCLAIMER: This video is provided for informational purposes only and does not constitute, and should not be construed as, investment, trading, financial, legal, accounting, tax, or other professional advice. It is not, and should not be considered, an offer, solicitation, recommendation, or inducement to buy or sell any securities or products, nor a basis for evaluating or entering into any transaction. Viewers are solely responsible for obtaining independent professional advice before making any investment or financial decision. All investments involve risk, including the possible loss of principal, and past performance is not a reliable indicator of future results.

Global One Media, or certain participants in this interview (including their associated companies), may have been compensated by — and may hold ownership interests in — the companies featured. Such interests may create a conflict of interest, and viewers should assume that Global One Media and these participants may have a financial interest in the subject matter. Stocks To Watch is a part of Global One Media Group Pte. Ltd. (https://globalonemedia.com), a Singapore-based content creation and media services company. The views expressed are solely those of the individuals and do not necessarily reflect the views of the company or its affiliates. No representation or warranty, express or implied, is made regarding the accuracy, completeness, or timeliness of the information contained herein.

Global One Media expressly disclaims all liability for any loss or damage arising from reliance on or use of this content. Third-party statements or opinions are the sole responsibility of their authors and are not endorsed, verified, or guaranteed by Global One Media. By watching this video, you acknowledge and agree that Global One Media operates under the laws of Singapore and that you are responsible for ensuring your compliance with the laws and regulations of your own jurisdiction. Reproduction, distribution, or republication of this video, in whole or in part, without the express written consent of Global One Media, is strictly prohibited.